Athersys announces summary results for Phase 1 safety study of its novel obesity drug
Athersys, Inc. (Nasdaq:ATHX) today announced top-line results from its Phase 1 clinical trial of ATHX-105, its orally administered drug candidate for the treatment of obesity. ATHX-105 was well- absorbed, providing good drug exposures, well-tolerated up to high doses, and had no negative effect on cardiovascular, hematology or other clinical parameters.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.